Immune responses to citrullinated and homocitrullinated peptides in healthy donors are not restricted to the HLA SE shared allele and can be selected into the memory pool.

Autor: Choudhury RH; Scancell Limited, University of Nottingham Biodiscovery Institute, Nottingham, UK., Daniels I; Scancell Limited, University of Nottingham Biodiscovery Institute, Nottingham, UK., Vaghela P; Scancell Limited, University of Nottingham Biodiscovery Institute, Nottingham, UK., Atabani S; Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, Nottingham, UK., Kirk T; Scancell Limited, University of Nottingham Biodiscovery Institute, Nottingham, UK., Symonds P; Scancell Limited, University of Nottingham Biodiscovery Institute, Nottingham, UK., Cook KW; Scancell Limited, University of Nottingham Biodiscovery Institute, Nottingham, UK., Al-Omari A; Scancell Limited, University of Nottingham Biodiscovery Institute, Nottingham, UK., Weston D; Scancell Limited, University of Nottingham Biodiscovery Institute, Nottingham, UK., Shah S; Scancell Limited, University of Nottingham Biodiscovery Institute, Nottingham, UK., Hutchinson D; Royal Cornwall Hospitals NHS Trust, Truro, Cornwall, UK., Paston SJ; Scancell Limited, University of Nottingham Biodiscovery Institute, Nottingham, UK., Metheringham RL; Scancell Limited, University of Nottingham Biodiscovery Institute, Nottingham, UK., Brentville VA; Scancell Limited, University of Nottingham Biodiscovery Institute, Nottingham, UK., Durrant LG; Scancell Limited, University of Nottingham Biodiscovery Institute, Nottingham, UK.; Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, Nottingham, UK.

Publikováno v: Immunology [Immunology] 2023 Aug; Vol. 169 (4), pp. 467-486. Date of Electronic Publication: 2023 Apr 13.

The Clinical and Prognostic Significance of Protein Arginine Deiminases 2 and 4 in Colorectal Cancer.

Autor: Gijon M; Scancell Limited, Biodiscovery Institute, University Park, Nottingham, United Kingdom., Metheringham RL; Scancell Limited, Biodiscovery Institute, University Park, Nottingham, United Kingdom., Toss MS; Division of Cancer and Stem Cells, Nottingham Breast Cancer Research Centre, School of Medicine, Nottingham City Hospital, The University of Nottingham, Nottingham, United Kingdom., Paston SJ; Scancell Limited, Biodiscovery Institute, University Park, Nottingham, United Kingdom, samanthapaston@scancell.co.uk., Durrant LG; Scancell Limited, Biodiscovery Institute, University Park, Nottingham, United Kingdom.; Division of Cancer and Stem Cells, Biodiscovery Institute, University Park, University of Nottingham, Nottingham, United Kingdom.

Publikováno v: Pathobiology : journal of immunopathology, molecular and cellular biology [Pathobiology] 2022; Vol. 89 (1), pp. 38-48. Date of Electronic Publication: 2021 Sep 16.

Homocitrullination of lysine residues mediated by myeloid-derived suppressor cells in the tumor environment is a target for cancer immunotherapy.

Autor: Cook KW; Scancell Ltd, Nottingham, UK., Xue W; Scancell Ltd, Nottingham, UK., Symonds P; Scancell Ltd, Nottingham, UK., Daniels I; Scancell Ltd, Nottingham, UK., Gijon M; Scancell Ltd, Nottingham, UK., Boocock D; School of Science and Technology, Nottingham Trent University, Nottingham, UK., Coveney C; School of Science and Technology, Nottingham Trent University, Nottingham, UK., Miles AK; School of Science and Technology, Nottingham Trent University, Nottingham, UK., Shah S; Scancell Ltd, Nottingham, UK., Atabani S; Biodiscovery Institute, University of Nottingham Faculty of Medicine and Health Sciences, Nottingham, UK., Choudhury RH; Scancell Ltd, Nottingham, UK., Vaghela P; Biodiscovery Institute, University of Nottingham Faculty of Medicine and Health Sciences, Nottingham, UK., Weston D; Scancell Ltd, Nottingham, UK., Metheringham RL; Scancell Ltd, Nottingham, UK., Brentville VA; Scancell Ltd, Nottingham, UK., Durrant LG; Scancell Ltd, Nottingham, UK lindy.durrant@nottingham.ac.uk.; Biodiscovery Institute, University of Nottingham Faculty of Medicine and Health Sciences, Nottingham, UK.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Jul; Vol. 9 (7).

Post-translational modifications such as citrullination are excellent targets for cancer therapy.

Autor: Brentville VA; Scancell Ltd, University of Nottingham Biodiscovery Institute, Science Road, University Park, Nottingham, NG7 2RD, UK. Electronic address: victoriabrentville@scancell.co.uk., Vankemmelbeke M; Scancell Ltd, University of Nottingham Biodiscovery Institute, Science Road, University Park, Nottingham, NG7 2RD, UK. Electronic address: mireillevankemmelbeke@scancell.co.uk., Metheringham RL; Scancell Ltd, University of Nottingham Biodiscovery Institute, Science Road, University Park, Nottingham, NG7 2RD, UK. Electronic address: rachaelmetheringham@scancell.co.uk., Durrant LG; Scancell Ltd, University of Nottingham Biodiscovery Institute, Science Road, University Park, Nottingham, NG7 2RD, UK; Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, Science Road, University Park, Nottingham, NG7 2RD, UK. Electronic address: lindy.durrant@nottingham.ac.uk.

Publikováno v: Seminars in immunology [Semin Immunol] 2020 Feb; Vol. 47, pp. 101393. Date of Electronic Publication: 2020 Jan 10.

Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial.

Autor: Patel PM; Academic Department of Clinical Oncology, Division of Cancer & Stem Cells, University of Nottingham, Nottingham, UK., Ottensmeier CH; Southampton Experimental Cancer Medicine Centre and Southampton University Hospitals, Faculty of Medicine, Southampton, UK., Mulatero C; St James's University Hospital, Leeds, UK., Lorigan P; Institute of Cancer Sciences, University of Manchester, The Christie NHS Foundation Trust, Manchester, UK., Plummer R; Northern Institute for Cancer Research, Medical School, University of Newcastle-upon-Tyne and Wear, UK., Pandha H; Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, UK., Elsheikh S; University of Nottingham, School of Medicine Queen's Medical Centre, Nottingham, UK., Hadjimichael E; University of Nottingham, School of Medicine Queen's Medical Centre, Nottingham, UK., Villasanti N; University of Nottingham, School of Medicine Queen's Medical Centre, Nottingham, UK., Adams SE; Scancell Limited, Academic Department of Clinical Oncology, University of Nottingham, Nottingham, UK., Cunnell M; Academic Department of Clinical Oncology, Division of Cancer & Stem Cells, University of Nottingham, Nottingham, UK., Metheringham RL; Scancell Limited, Academic Department of Clinical Oncology, University of Nottingham, Nottingham, UK., Brentville VA; Scancell Limited, Academic Department of Clinical Oncology, University of Nottingham, Nottingham, UK., Machado L; Scancell Limited, Academic Department of Clinical Oncology, University of Nottingham, Nottingham, UK., Daniels I; Scancell Limited, Academic Department of Clinical Oncology, University of Nottingham, Nottingham, UK., Gijon M; Scancell Limited, Academic Department of Clinical Oncology, University of Nottingham, Nottingham, UK., Hannaman D; Ichor Medical Systems, Inc., San Diego, CA, USA., Durrant LG; Academic Department of Clinical Oncology, Division of Cancer & Stem Cells, University of Nottingham, Nottingham, UK.; Scancell Limited, Academic Department of Clinical Oncology, University of Nottingham, Nottingham, UK.

Publikováno v: Oncoimmunology [Oncoimmunology] 2018 Feb 22; Vol. 7 (6), pp. e1433516. Date of Electronic Publication: 2018 Feb 22 (Print Publication: 2018).